[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-oxidative-stress\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-oxidative-stress":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622099","efficacy-evaluation-study-of-vitamin-c-and-glutathione-liquid-sachet-100622099",false,"NCT07379216","Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet","Inclusion Criteria:\n\n* Healthy male or female adults, aged 18-65 years old;\n* Commitment not to use products having activity comparable with that of the product to be tested during the study period;\n* Free of any dermatological or systemic disorder that would interfere with results.\n\nExclusion Criteria:\n\n* Subject with obvious skin surface damage;\n* Subject who had oral or topical medication which may affect skin condition within 1 month;\n* Individuals with known allergies to cosmetics, medications, or foods (especially those allergic to legumes\u002Fsoy);\n* Pregnant or breastfeeding individuals;\n* Received facial laser therapy, chemical peeling in the past 2 months.\n* Individuals unwilling to allow publication or public disclosure of photographs taken as part of the study results",true,"ALL","18 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to evaluate the effect of liquid vitamin C and glutathione supplements on human skin condition improvement and anti-oxidation.",[27,28],"Skin Condition","Anti-Oxidative Stress",[30,31],"Vitamin C supplement","Glutathione supplement","RECRUITING","2026-02-02",{"date":35,"type":36},"2026-02-04","ACTUAL",{"date":38,"type":36},"2026-01-24",{"date":40,"type":21},"2026-06-01",{"name":42,"class":43},"TCI Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100620650","comparing-n-acetylcysteine-nac-versus-alpha-lipoic-acid-ala-as-adjuncts-for-postoperative-pain-management-after-laparoscopic-appendectomy-100620650","NCT07360379","Comparing N-Acetylcysteine (NAC) Versus Alpha-Lipoic Acid (ALA) as Adjuncts for Postoperative Pain Management After Laparoscopic Appendectomy","Inclusion Criteria:\n\n* Age 18-65 years, either sex\n\n  * ASA physical status I-III\n  * Undergoing laparoscopic appendectomy\n  * Able to provide informed consent and take oral medications postoperatively\n\nExclusion Criteria:\n\n* Chronic opioid use or chronic pain disorder\n* Pregnancy or lactation\n* Hepatic or renal impairment\n* Known hypersensitivity to NAC or ALA\n* Complicated appendicitis requiring open surgery or ICU admission\n\nExclusion Criteria:\n\n\\-",{"count":52,"type":21},180,[24],"Postoperative pain remains a major concern following laparoscopic appendectomy, despite advances in minimally invasive surgery and multimodal analgesia. Inadequate pain control delays recovery, prolongs hospital stay, and increases opioid consumption with associated adverse effects. Therefore, identifying safe adjunct therapies that enhance analgesia and reduce opioid requirements is an important clinical goal.\n\nOxidative stress and inflammation play a critical role in the development and maintenance of postoperative pain. Surgical trauma induces the generation of reactive oxygen species, which sensitize peripheral nociceptors and enhance central pain transmission.\n\nAntioxidants capable of modulating oxidative stress and inflammatory pathways may therefore offer analgesic benefits beyond conventional analgesics.\n\nN-Acetylcysteine (NAC), a glutathione precursor, has demonstrated anti-inflammatory and analgesic properties in both experimental and clinical settings. It reduces oxidative stress, improves microcirculation, and modulates nociceptive signaling.\n\nAlpha-Lipoic Acid (ALA) is another potent antioxidant that acts as a cofactor in mitochondrial metabolism and has proven efficacy in neuropathic pain conditions. However, its role in acute postoperative pain has not been fully investigated.\n\nTo our knowledge, no clinical trial has directly compared NAC and ALA in the perioperative setting, and their effects following laparoscopic appendectomy remain unstudied. This randomized controlled trial aims to evaluate the efficacy and safety of NAC and ALA as adjuncts to standard analgesia, with the goal of estimating their effect on postoperative opioid consumption and pain intensity. The results will provide preliminary data to guide larger definitive studies.\n\nAim of the study The aim of this study is to evaluate and compare the efficacy and safety of N-acetylcysteine (NAC) and alpha-lipoic acid (ALA) as adjuncts to standard postoperative analgesia in patients undergoing laparoscopic appendectomy. Specifically, the study seeks to determine their effects on postoperative pain intensity, opioid consumption, and recovery profile in the early postoperative period.",[56,57,58],"Laparoscopic Appendectomy","Pain Management","Anti Oxidative Stress",[60,61,62,63,64],"Postoperative pain","Laparoscopic appendectomy","N- acetyl cysteine","Alpha lipoic acid","pain management","NOT_YET_RECRUITING","2026-01-16",{"date":68,"type":36},"2026-01-22",{"date":70,"type":21},"2025-12-28",{"date":72,"type":21},"2026-05",{"name":74,"class":75},"Ain Shams University","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":44},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)",{"count":83,"type":21},118,[24],"The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[87,88,89,90,58,91,92,93,94],"Rheumatic Arthritis","Rheumatoid Arthritis (RA) Prevention","Inflamation","Antioxidant","Anti Aging","C Reactive Protein","Methotrexate","Quality of Life Outcomes","2025-07-21",{"date":97,"type":36},"2025-07-28",{"date":99,"type":21},"2025-08-01",{"date":40,"type":21},{"name":74,"class":75}]